TMCnet News

Research and Markets: OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018
[April 24, 2015]

Research and Markets: OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018


Research and Markets (http://www.researchandmarkets.com/research/r72bzf/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Cushing's Syndrome - Opportunity Analysis and Forecasts to 2018" report to their offering.

Global Cushing's Syndrome Treatment Market Value Soaring to Almost $500 Million by 2018.

The global Cushing's Syndrome (CS) treatment market will expand rapidly in value from approximately $179 million in 2013 to $499 million by 2018, representing an impressive Compound Annual Growth Rate (CAGR) of 22.74%.

The report states that of the six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), the US was the largest contributor to CS treatment revenues in 2013, generting around $129 million. The US will see this figure rocket to $371 million by 2018, claiming a 74% share of the global market.



Increasing disease prevalence will be a major driver behind the significant growth in the CS therapeutics arena, along with the arrivals of Novartis' Signifor LAR (pasireotide), a more convenient dosing regimen for Signifor, in the 6MM in 2018 and HRA Pharma's Ketoconazole HRA (ketoconazole) in Europe in 2015.

Shaan Thakerar, MSc, Analyst covering Cardiovascular & Metabolic Disorders, says: Additionally, the US launch of second-generation steroidogenesis inhibitors, such as Cortendo AB's NormoCort (COR-003) and Novartis' LCI699, will also boost the market over the forecast period.


These two drugs will be heralded by physicians and patients alike, as they will satisfy the high unmet need for safer and more effective products targeting CS, namely severe forms of the condition.

Despite these various products' anticipated introductions into their respective markets,we believe that considerable opportunities remain for pharmaceutical and biotechnology companies to develop improved treatment options.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Current Treatment Options

6 Unmet Needs Assessment and Oppportunity Analysis

7 Research and Development Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

For more information visit http://www.researchandmarkets.com/research/r72bzf/opportunityanalyze


[ Back To TMCnet.com's Homepage ]